Novo Nordisk shares fall on weight loss drug trial results Proactive Investors USA
Month: March 2025
Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain. – Barron’s
Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain. Barron’s
Roche announces hub for cardiovascular, renal and metabolism research
Roche has announced the launch of the Roche Genentech Innovation Center Boston, which will serve as…
Eli Lilly plans launch of weight-loss drug in emerging markets by 2026, CFO says – TradingView
Eli Lilly plans launch of weight-loss drug in emerging markets by 2026, CFO says TradingView
Novo Nordisk stock sinks on weight loss drug trial letdown – Yahoo Finance
Novo Nordisk stock sinks on weight loss drug trial letdown Yahoo Finance
Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study – Investopedia
Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study Investopedia
Dr Jack Mosley on ‘gamechanger’ weight loss method to beat ‘food noise’ – Yahoo News UK
Dr Jack Mosley on ‘gamechanger’ weight loss method to beat ‘food noise’ Yahoo News UK
Novo Dips After CagriSema’s Latest Lower-Than-Expected Weight Loss Readout – BioSpace
Novo Dips After CagriSema’s Latest Lower-Than-Expected Weight Loss Readout BioSpace
Michael Mosley’s son writes book on weight-loss drugs continuing father’s work – The Independent
Michael Mosley’s son writes book on weight-loss drugs continuing father’s work The Independent
Novo Nordisk’s CagriSema shows nearly 16 percent weight loss – PharmaLive
Novo Nordisk’s CagriSema shows nearly 16 percent weight loss PharmaLive